
Alzheimer's disease (AD) is characterised by accumulations of beta-amyloid (Aβ) in the brain.
Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Role of Galectin-3 in Alzheimer's Disease
The Core Concept: Researchers at Lund University, working with collaborators in Spain, have discovered that the immune-cell protein galectin-3 actively reshapes beta-amyloid (Aβ) plaques in Alzheimer's disease (AD) rather than merely accumulating around them. By binding directly to Aβ fibers and regulating how brain immune cells called microglia process amyloid, galectin-3 drives neuroinflammation and accelerates damage to surrounding nerve cells.
Key Distinction/Mechanism: Galectin-3 binds strongly to Aβ and operates simultaneously in two locations: outside microglia on the plaque surface, where it blocks a step in amyloid fibril multiplication and alters fibril shape, and inside microglial lysosomes, where it directs amyloid breakdown. In cell experiments, these reshaped fibrils damaged nerve cells, whereas removing galectin-3 in mice with an Alzheimer's-like condition produced smaller, more tightly packed plaques, markedly less nerve-ending damage, and a microglial shift from an aggressive state to a protective state rich in the immune receptor TREM2. Unlike existing AD antibody therapies that clear amyloid without curbing brain inflammation, targeting galectin-3 addresses both plaque structure and the damaging immune response.
Origin/History: In a previous study, the Lund University research team demonstrated for the first time that galectin-3 levels increase in the brains of people with AD and that removing the protein reduces brain inflammation. The current research builds on that precedent by revealing the direct physical and cellular mechanisms linking galectin-3 to Aβ plaque architecture and nerve injury.
Major Frameworks/Components:
- Dual-Site Galectin-3 Activity: Galectin-3 acts concurrently outside microglia to physically remodel growing Aβ fibrils and inside microglial lysosomes to steer intracellular amyloid degradation. This dual localization explains how a single immune protein alters both extracellular plaque structure and cellular clearance pathways.
- Microglial State Transition and TREM2: Inactivating galectin-3 in mouse models shifts microglia from a harmful, inflammatory phenotype to a protective state enriched in the receptor TREM2. Because TREM2 supports the brain's immune defense and influences AD risk, modulating this transition reduces collateral damage to adjacent nerve endings.
- Translational Validation Models: Experiments in mice established a clear cause-and-effect relationship among galectin-3 removal, tighter plaque compaction, and reduced nerve-ending injury. Complementary analyses of brain tissue from nine human individuals confirmed a strong correlation with human disease, while cell cultures verified the neurotoxicity of galectin-3-reshaped fibrils.








.jpg)


.png)



.jpg)


